Breaking News

Recipharm Invests €2.6M in Kaysersberg Facility

The Kaysersberg facility specializes in producing sterile liquids for therapeutic areas including eye care and ear drops.

Recipharm is investing €2.6 million in additional manufacturing capacity to support increased demand at its sterile manufacturing facility in Kaysersberg, France. The Kaysersberg facility specializes in producing sterile liquids for therapeutic areas including eye care and ear drops.

Part of the company’s phased expansion plan for the facility, this investment will add additional capacity and capabilities for the company’s customers, as well as future business.

Yves Buelens, General Manager at the Kaysersberg facility, said: “It’s great to see more investment into our facility. Our sustained growth over the last few years is testament to our talented and passionate team. We continue to look for new ways to develop our offering and implement our continued growth plan, which will naturally bring more employment opportunities to the region.”

 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters